16 May 2023
SHARE NOW
ATW
Cell Therapy
Gene Therapy
GMP
Raw Materials
Scaling Up
This Briefing from Advanced Therapies Week 2023 focusses on ancillary material considerations to facilitate a seamless transition into GMP manufacturing.
During this session, Bernd Leistler, Vice President of Production at Sartorius CellGenix is joined by Tess Kitchener, Vice President, BaseCamp Business Development at Elevatebio, Isaac Zentner, Associate Director of Process Development at Carisma Therapeutics, Stefano Baila, Managing Director at Eurofins and Lili Belcastro, Senior Principal Scientist, Cell and Gene Therapy Raw Materials at Bristol Myers Squibb.
This Briefing was presented at Advanced Therapies Week 2023, in partnership with Sartorius CellGenix.
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023
